Posts Tagged rate

Mocon launches WVTR instrument for ultra-high barrier films

Friday, March 22nd, 2013 | Permalink

Mocon Inc. , a manufacturer of package integrity instrumentation, has developed a new system to measure the water vapor transmission rate (WVTR) of ultra-high barrier films with “greater sensitivity than ever before possible,” the company said. Tagging Options Domain:  All Sites Keywords:  plastics packaging Mocon barrier films integrity read more

Taken from:
Mocon launches WVTR instrument for ultra-high barrier films

Florida Grandmother, Renter Describes Foreclosure Eviction …

Friday, December 21st, 2012 | Permalink

Gayle Cook and her late husband, William, created the medical device company Cook Group in Indiana in 1963. Gayle continues to … ( Chris Howell, Hoosier-Times, Inc. ) ….. Gun Debate Must Avoid Crazy 2nd Amendment Claims. Even With Boehner's Bold Offer, Fiscal-Cliff Gaps Remain. Bloomberg View RSS Feed ». The Interest Rate Spike Story Seems Incoherent. Will 2013 Bring Financial Reform?

Read the original:
Florida Grandmother, Renter Describes Foreclosure Eviction …

For AEterna Zentaris And Keryx (NASDAQ: KERX), Phase 3 Set For Success; Takeover Likely

Monday, December 19th, 2011 | Permalink

Keryx Biopharmaceuticals (NASDAQ: KERX) is an emerging small-cap biopharma company that has a pair of lead compounds in late-stage, Phase 3 development for the treatment of cancer (perifosine) and renal disease (Zerenex), under Special Protocol Assessment (SPA) agreements with the FDA. KERX is Aeterna Zentaris ’ partner and licensee for perifosine in the USA, Canada and Mexico. On Tuesday, Seeking Alpha contributor Jeremy Richards of Private Wealth Fund wrote: “Without question, our company believes strongly in AEterna Zentaris’ (AEZS) lead drug candidate and the likelihood of a takeover of the company.” Richards summarized some of his previous points and provided additional, new analysis of the clinical data to support his position. About Perifosine Richards wrote: “The P3 Perifosine, in combination with Xeloda (Capecitabine) X-Pect study of Keryx, is a trial for a drug combination used to treat metastatic colorectal cancer (mCRC). The combination is referred to as PCAP for Perifosine-Capacitabine. This is a very important study because the number of deaths occurring each year as estimated by WHO is 610,000 worldwide, including 142,570 new cases and 51,370 deaths in the U.S. in 2010. The death rate from mCRC is about 17 per 100,000 people annually in the U.S. CRC is the second most common cancer after lung cancer and more lives are lost each year to colorectal cancer than to breast cancer and AIDS combined. More than 60% of cancers are detected in their late stages. Preliminary evidence is that PCAP is the most effective drug combination known for mCRC.” Read the full article on Seeking Alpha.

Read this article:
For AEterna Zentaris And Keryx (NASDAQ: KERX), Phase 3 Set For Success; Takeover Likely